Key result
This review analyzes the attributes, merits, and limitations of experimentally tested vaccines against group B coxsackieviruses for preventing infections such as myocarditis and type 1 diabetes.
Why the study?
Group B coxsackieviruses cause diseases such as myocarditis and type 1 diabetes, yet no vaccines against these viruses are currently available.
This review highlights the current state of experimental vaccines against Group B Coxsackieviruses and their potential to prevent viral myocarditis and type 1 diabetes.
Experimental coxsackievirus B vaccines merit further development; leaves open their role in preventing myocarditis and type 1 diabetes.
The group B coxsackieviruses (CVBs) exist in six serotypes (CVB1 to CVB6). Disease associations have been reported for most serotypes, and multiple serotypes can cause similar diseases. For example, CVB1, CVB3, and CVB5 are generally implicated in the causation of myocarditis, whereas CVB1 and CVB4 could accelerate the development of type 1 diabetes (T1D). Yet, no vaccines against these viruses are currently available. In this review, we have analyzed the attributes of experimentally tested vaccines and discussed their merits and demerits or limitations, as well as their impact in preventing infections, most importantly myocarditis and T1D.
No takes yet. Share an insight, caveat, or question.
Mone et al. (2023) conducted a review in Group B coxsackievirus infections, myocarditis, and type 1 diabetes. Vaccines against Group B Coxsackieviruses was evaluated. This review analyzes the attributes, merits, and limitations of experimentally tested vaccines against group B coxsackieviruses for preventing infections such as myocarditis and type 1 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: